Article | January 11, 2021

Commercializing Disruptive Technologies In Advanced Therapies

Source: Invetech
Future Technology Science

Invetech panel discussion at Phacilitate Advanced Therapies Connect 2020

Our panel discussion at the first virtual Phacilitate Advanced Therapies Connect conference brought together three companies with disruptive technologies in the advanced therapies space.

Comprising of Kevin Alessandri, CEO/CTO, Treefrog Therapeutics, Vincent Ronfard, Chief Innovation Officer, CUTISS, and Rob Schutte, Executive Director, Process Development, Humacyte, the panel shared the journeys of their respective companies – all the way from the back of the napkin to the bedside.

access the Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Invetech